nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—S-Adenosylmethionine—GNMT—liver cancer	0.0136	0.461	CrCbGaD
Nelarabine—DCK—Doxorubicin—Epirubicin—liver cancer	0.00872	0.519	CbGdCrCtD
Nelarabine—Adenosine triphosphate—TNK2—liver cancer	0.00842	0.285	CrCbGaD
Nelarabine—DCK—Epirubicin—Doxorubicin—liver cancer	0.00807	0.481	CbGdCrCtD
Nelarabine—POLA1—Leading Strand Synthesis—PCNA—liver cancer	0.00647	0.025	CbGpPWpGaD
Nelarabine—POLA1—Removal of the Flap Intermediate—PCNA—liver cancer	0.00647	0.025	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—SIX3—liver cancer	0.00607	0.0234	CbGpPWpGaD
Nelarabine—POLA1—Processive synthesis on the lagging strand—PCNA—liver cancer	0.00581	0.0224	CbGpPWpGaD
Nelarabine—POLA1—G1/S-Specific Transcription—PCNA—liver cancer	0.00554	0.0214	CbGpPWpGaD
Nelarabine—Hyporeflexia—Doxorubicin—liver cancer	0.0048	0.00691	CcSEcCtD
Nelarabine—Pneumothorax—Epirubicin—liver cancer	0.00474	0.00682	CcSEcCtD
Nelarabine—POLA1—Lagging Strand Synthesis—PCNA—liver cancer	0.00468	0.0181	CbGpPWpGaD
Nelarabine—Pain in extremity—Sorafenib—liver cancer	0.00463	0.00667	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—SERPINA1—liver cancer	0.00446	0.0172	CbGpPWpGaD
Nelarabine—Pneumothorax—Doxorubicin—liver cancer	0.00439	0.00631	CcSEcCtD
Nelarabine—POLA1—Telomere C-strand (Lagging Strand) Synthesis—PCNA—liver cancer	0.00435	0.0168	CbGpPWpGaD
Nelarabine—Dehydration—Sorafenib—liver cancer	0.00431	0.0062	CcSEcCtD
Nelarabine—Hypokalaemia—Sorafenib—liver cancer	0.00422	0.00607	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00417	0.006	CcSEcCtD
Nelarabine—Febrile neutropenia—Epirubicin—liver cancer	0.00392	0.00564	CcSEcCtD
Nelarabine—Transaminases increased—Epirubicin—liver cancer	0.00388	0.00558	CcSEcCtD
Nelarabine—Polyp—Epirubicin—liver cancer	0.00388	0.00558	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—ABL1—liver cancer	0.00379	0.0146	CbGpPWpGaD
Nelarabine—Neutropenia—Sorafenib—liver cancer	0.00374	0.00539	CcSEcCtD
Nelarabine—Hypomagnesaemia—Epirubicin—liver cancer	0.00371	0.00534	CcSEcCtD
Nelarabine—Febrile neutropenia—Doxorubicin—liver cancer	0.00363	0.00522	CcSEcCtD
Nelarabine—POLA1—Extension of Telomeres—PCNA—liver cancer	0.00361	0.0139	CbGpPWpGaD
Nelarabine—Pneumonia—Sorafenib—liver cancer	0.00359	0.00517	CcSEcCtD
Nelarabine—Transaminases increased—Doxorubicin—liver cancer	0.00359	0.00516	CcSEcCtD
Nelarabine—Polyp—Doxorubicin—liver cancer	0.00359	0.00516	CcSEcCtD
Nelarabine—Infestation—Sorafenib—liver cancer	0.00357	0.00514	CcSEcCtD
Nelarabine—Infestation NOS—Sorafenib—liver cancer	0.00357	0.00514	CcSEcCtD
Nelarabine—Cyst—Epirubicin—liver cancer	0.00353	0.00508	CcSEcCtD
Nelarabine—Neuropathy peripheral—Sorafenib—liver cancer	0.0035	0.00504	CcSEcCtD
Nelarabine—POLA1—Extension of Telomeres—TERT—liver cancer	0.00349	0.0135	CbGpPWpGaD
Nelarabine—Stomatitis—Sorafenib—liver cancer	0.00348	0.00501	CcSEcCtD
Nelarabine—Hypomagnesaemia—Doxorubicin—liver cancer	0.00343	0.00494	CcSEcCtD
Nelarabine—Burning sensation—Epirubicin—liver cancer	0.00339	0.00489	CcSEcCtD
Nelarabine—Neuralgia—Epirubicin—liver cancer	0.00339	0.00489	CcSEcCtD
Nelarabine—Paralysis—Epirubicin—liver cancer	0.00339	0.00489	CcSEcCtD
Nelarabine—Hepatobiliary disease—Sorafenib—liver cancer	0.00338	0.00486	CcSEcCtD
Nelarabine—Epistaxis—Sorafenib—liver cancer	0.00337	0.00485	CcSEcCtD
Nelarabine—POLA1—DNA strand elongation—PCNA—liver cancer	0.00334	0.0129	CbGpPWpGaD
Nelarabine—Nystagmus—Epirubicin—liver cancer	0.0033	0.00475	CcSEcCtD
Nelarabine—Cyst—Doxorubicin—liver cancer	0.00326	0.0047	CcSEcCtD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—PCNA—liver cancer	0.00326	0.0126	CbGpPWpGaD
Nelarabine—Urinary tract disorder—Sorafenib—liver cancer	0.00316	0.00456	CcSEcCtD
Nelarabine—Neuritis—Epirubicin—liver cancer	0.00316	0.00455	CcSEcCtD
Nelarabine—Connective tissue disorder—Sorafenib—liver cancer	0.00315	0.00453	CcSEcCtD
Nelarabine—Urethral disorder—Sorafenib—liver cancer	0.00314	0.00452	CcSEcCtD
Nelarabine—Paralysis—Doxorubicin—liver cancer	0.00314	0.00452	CcSEcCtD
Nelarabine—Neuralgia—Doxorubicin—liver cancer	0.00314	0.00452	CcSEcCtD
Nelarabine—Burning sensation—Doxorubicin—liver cancer	0.00314	0.00452	CcSEcCtD
Nelarabine—Pleural effusion—Epirubicin—liver cancer	0.00308	0.00443	CcSEcCtD
Nelarabine—Nystagmus—Doxorubicin—liver cancer	0.00305	0.0044	CcSEcCtD
Nelarabine—Fungal infection—Epirubicin—liver cancer	0.00305	0.0044	CcSEcCtD
Nelarabine—Adenosine triphosphate—AKT1—liver cancer	0.00302	0.102	CrCbGaD
Nelarabine—DGUOK—Metabolism—UGDH—liver cancer	0.00301	0.0116	CbGpPWpGaD
Nelarabine—Cardiac disorder—Sorafenib—liver cancer	0.00297	0.00428	CcSEcCtD
Nelarabine—Neuritis—Doxorubicin—liver cancer	0.00292	0.00421	CcSEcCtD
Nelarabine—Angiopathy—Sorafenib—liver cancer	0.00291	0.00419	CcSEcCtD
Nelarabine—Rigors—Epirubicin—liver cancer	0.00289	0.00416	CcSEcCtD
Nelarabine—Mediastinal disorder—Sorafenib—liver cancer	0.00289	0.00416	CcSEcCtD
Nelarabine—Petechiae—Epirubicin—liver cancer	0.00287	0.00413	CcSEcCtD
Nelarabine—Adenosine triphosphate—ABL1—liver cancer	0.00285	0.0965	CrCbGaD
Nelarabine—Pleural effusion—Doxorubicin—liver cancer	0.00285	0.0041	CcSEcCtD
Nelarabine—DGUOK—Metabolism—EPT1—liver cancer	0.00283	0.0109	CbGpPWpGaD
Nelarabine—Fungal infection—Doxorubicin—liver cancer	0.00283	0.00407	CcSEcCtD
Nelarabine—Blood disorder—Epirubicin—liver cancer	0.00282	0.00406	CcSEcCtD
Nelarabine—Mental disorder—Sorafenib—liver cancer	0.00281	0.00404	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—ABL1—liver cancer	0.0028	0.0108	CbGpPWpGaD
Nelarabine—Malnutrition—Sorafenib—liver cancer	0.00279	0.00402	CcSEcCtD
Nelarabine—Dysgeusia—Sorafenib—liver cancer	0.00273	0.00393	CcSEcCtD
Nelarabine—POLA1—DNA Replication—PCNA—liver cancer	0.00269	0.0104	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—TAT—liver cancer	0.00269	0.0104	CbGpPWpGaD
Nelarabine—Rigors—Doxorubicin—liver cancer	0.00267	0.00385	CcSEcCtD
Nelarabine—Petechiae—Doxorubicin—liver cancer	0.00265	0.00382	CcSEcCtD
Nelarabine—Blood disorder—Doxorubicin—liver cancer	0.00261	0.00376	CcSEcCtD
Nelarabine—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00259	0.00373	CcSEcCtD
Nelarabine—Anaemia—Sorafenib—liver cancer	0.00258	0.00371	CcSEcCtD
Nelarabine—Hypocalcaemia—Epirubicin—liver cancer	0.00258	0.00371	CcSEcCtD
Nelarabine—Hyperuricaemia—Epirubicin—liver cancer	0.00254	0.00366	CcSEcCtD
Nelarabine—POLA1—DNA Replication Pre-Initiation—PSMD10—liver cancer	0.00251	0.00969	CbGpPWpGaD
Nelarabine—POLA1—DNA Replication Pre-Initiation—PSMA4—liver cancer	0.00251	0.00969	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—GSTM1—liver cancer	0.0025	0.00966	CbGpPWpGaD
Nelarabine—Leukopenia—Sorafenib—liver cancer	0.0025	0.00359	CcSEcCtD
Nelarabine—Dysarthria—Epirubicin—liver cancer	0.00249	0.00359	CcSEcCtD
Nelarabine—Blood bilirubin increased—Epirubicin—liver cancer	0.00249	0.00359	CcSEcCtD
Nelarabine—Loss of consciousness—Sorafenib—liver cancer	0.00245	0.00353	CcSEcCtD
Nelarabine—Cough—Sorafenib—liver cancer	0.00243	0.0035	CcSEcCtD
Nelarabine—Gait disturbance—Epirubicin—liver cancer	0.00242	0.00348	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—liver cancer	0.0024	0.00927	CbGpPWpGaD
Nelarabine—Blood uric acid increased—Epirubicin—liver cancer	0.0024	0.00346	CcSEcCtD
Nelarabine—Coordination abnormal—Epirubicin—liver cancer	0.0024	0.00346	CcSEcCtD
Nelarabine—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.0024	0.00345	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—ABL1—liver cancer	0.00239	0.00922	CbGpPWpGaD
Nelarabine—Hypocalcaemia—Doxorubicin—liver cancer	0.00238	0.00343	CcSEcCtD
Nelarabine—Myalgia—Sorafenib—liver cancer	0.00237	0.00342	CcSEcCtD
Nelarabine—Arthralgia—Sorafenib—liver cancer	0.00237	0.00342	CcSEcCtD
Nelarabine—Hyperuricaemia—Doxorubicin—liver cancer	0.00235	0.00339	CcSEcCtD
Nelarabine—Dysarthria—Doxorubicin—liver cancer	0.00231	0.00332	CcSEcCtD
Nelarabine—Blood bilirubin increased—Doxorubicin—liver cancer	0.00231	0.00332	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—AHR—liver cancer	0.00231	0.0089	CbGpPWpGaD
Nelarabine—Infection—Sorafenib—liver cancer	0.00226	0.00326	CcSEcCtD
Nelarabine—Gait disturbance—Doxorubicin—liver cancer	0.00224	0.00322	CcSEcCtD
Nelarabine—Nervous system disorder—Sorafenib—liver cancer	0.00223	0.00321	CcSEcCtD
Nelarabine—Thrombocytopenia—Sorafenib—liver cancer	0.00223	0.00321	CcSEcCtD
Nelarabine—Coordination abnormal—Doxorubicin—liver cancer	0.00222	0.0032	CcSEcCtD
Nelarabine—Blood uric acid increased—Doxorubicin—liver cancer	0.00222	0.0032	CcSEcCtD
Nelarabine—Neuropathy—Epirubicin—liver cancer	0.00221	0.00319	CcSEcCtD
Nelarabine—POLA1—Synthesis of DNA—PSMA4—liver cancer	0.00219	0.00846	CbGpPWpGaD
Nelarabine—POLA1—Synthesis of DNA—PSMD10—liver cancer	0.00219	0.00846	CbGpPWpGaD
Nelarabine—Anorexia—Sorafenib—liver cancer	0.00217	0.00312	CcSEcCtD
Nelarabine—Coma—Epirubicin—liver cancer	0.00215	0.0031	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—liver cancer	0.00215	0.0083	CbGpPWpGaD
Nelarabine—Neoplasm—Epirubicin—liver cancer	0.00213	0.00307	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—MAPK14—liver cancer	0.00211	0.00813	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00207	0.00299	CcSEcCtD
Nelarabine—Hypertonia—Epirubicin—liver cancer	0.00207	0.00298	CcSEcCtD
Nelarabine—POLA1—DNA Replication—PSMD10—liver cancer	0.00206	0.00794	CbGpPWpGaD
Nelarabine—POLA1—DNA Replication—PSMA4—liver cancer	0.00206	0.00794	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—PCNA—liver cancer	0.00205	0.00791	CbGpPWpGaD
Nelarabine—Neuropathy—Doxorubicin—liver cancer	0.00205	0.00295	CcSEcCtD
Nelarabine—Sepsis—Epirubicin—liver cancer	0.00205	0.00295	CcSEcCtD
Nelarabine—Mental disability—Epirubicin—liver cancer	0.00205	0.00295	CcSEcCtD
Nelarabine—Dyspnoea—Sorafenib—liver cancer	0.00203	0.00292	CcSEcCtD
Nelarabine—Coma—Doxorubicin—liver cancer	0.00199	0.00287	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—PSMD10—liver cancer	0.00198	0.00764	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—PSMA4—liver cancer	0.00198	0.00764	CbGpPWpGaD
Nelarabine—Decreased appetite—Sorafenib—liver cancer	0.00198	0.00285	CcSEcCtD
Nelarabine—Neoplasm—Doxorubicin—liver cancer	0.00197	0.00284	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Sorafenib—liver cancer	0.00197	0.00283	CcSEcCtD
Nelarabine—Fatigue—Sorafenib—liver cancer	0.00196	0.00283	CcSEcCtD
Nelarabine—Pain—Sorafenib—liver cancer	0.00195	0.0028	CcSEcCtD
Nelarabine—Constipation—Sorafenib—liver cancer	0.00195	0.0028	CcSEcCtD
Nelarabine—Hypertonia—Doxorubicin—liver cancer	0.00191	0.00275	CcSEcCtD
Nelarabine—Sepsis—Doxorubicin—liver cancer	0.00189	0.00273	CcSEcCtD
Nelarabine—Mental disability—Doxorubicin—liver cancer	0.00189	0.00273	CcSEcCtD
Nelarabine—Gastrointestinal pain—Sorafenib—liver cancer	0.00186	0.00268	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.00186	0.00718	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CPT1B—liver cancer	0.00183	0.00705	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GLUL—liver cancer	0.00183	0.00705	CbGpPWpGaD
Nelarabine—Abdominal pain—Sorafenib—liver cancer	0.0018	0.00259	CcSEcCtD
Nelarabine—Body temperature increased—Sorafenib—liver cancer	0.0018	0.00259	CcSEcCtD
Nelarabine—POLA1—S Phase—PSMA4—liver cancer	0.0018	0.00694	CbGpPWpGaD
Nelarabine—POLA1—S Phase—PSMD10—liver cancer	0.0018	0.00694	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—NR1H4—liver cancer	0.00176	0.0068	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN1A—liver cancer	0.00176	0.00678	CbGpPWpGaD
Nelarabine—Hypoglycaemia—Epirubicin—liver cancer	0.00175	0.00253	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—ABL1—liver cancer	0.00175	0.00675	CbGpPWpGaD
Nelarabine—POLA1—Telomere Maintenance—H2AFX—liver cancer	0.00175	0.00675	CbGpPWpGaD
Nelarabine—Lethargy—Epirubicin—liver cancer	0.00175	0.00251	CcSEcCtD
Nelarabine—DGUOK—Metabolism—GSTA3—liver cancer	0.00173	0.00668	CbGpPWpGaD
Nelarabine—Osteoarthritis—Epirubicin—liver cancer	0.00171	0.00246	CcSEcCtD
Nelarabine—Pain in extremity—Epirubicin—liver cancer	0.00171	0.00246	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—SERPINE1—liver cancer	0.0017	0.00655	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—PSMA4—liver cancer	0.00167	0.00644	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—PSMD10—liver cancer	0.00167	0.00644	CbGpPWpGaD
Nelarabine—POLA1—Telomere Maintenance—PCNA—liver cancer	0.00164	0.00632	CbGpPWpGaD
Nelarabine—Asthenia—Sorafenib—liver cancer	0.00163	0.00235	CcSEcCtD
Nelarabine—S-Adenosylmethionine—CYP2E1—liver cancer	0.00163	0.0551	CrCbGaD
Nelarabine—Hypoglycaemia—Doxorubicin—liver cancer	0.00162	0.00234	CcSEcCtD
Nelarabine—Lethargy—Doxorubicin—liver cancer	0.00162	0.00233	CcSEcCtD
Nelarabine—Ataxia—Epirubicin—liver cancer	0.00161	0.00232	CcSEcCtD
Nelarabine—Blood creatinine increased—Epirubicin—liver cancer	0.0016	0.00231	CcSEcCtD
Nelarabine—Dehydration—Epirubicin—liver cancer	0.00159	0.00229	CcSEcCtD
Nelarabine—Pain in extremity—Doxorubicin—liver cancer	0.00158	0.00228	CcSEcCtD
Nelarabine—Osteoarthritis—Doxorubicin—liver cancer	0.00158	0.00228	CcSEcCtD
Nelarabine—DGUOK—Metabolism—GSTA4—liver cancer	0.00158	0.00611	CbGpPWpGaD
Nelarabine—POLA1—Telomere Maintenance—TERT—liver cancer	0.00158	0.0061	CbGpPWpGaD
Nelarabine—Hypokalaemia—Epirubicin—liver cancer	0.00156	0.00224	CcSEcCtD
Nelarabine—Diarrhoea—Sorafenib—liver cancer	0.00156	0.00224	CcSEcCtD
Nelarabine—DGUOK—Metabolism—GSTA2—liver cancer	0.00154	0.00595	CbGpPWpGaD
Nelarabine—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00154	0.00222	CcSEcCtD
Nelarabine—Muscular weakness—Epirubicin—liver cancer	0.00151	0.00217	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CDKN2A—liver cancer	0.00151	0.00583	CbGpPWpGaD
Nelarabine—Dizziness—Sorafenib—liver cancer	0.00151	0.00217	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—PCNA—liver cancer	0.0015	0.00579	CbGpPWpGaD
Nelarabine—Abdominal distension—Epirubicin—liver cancer	0.00149	0.00214	CcSEcCtD
Nelarabine—Ataxia—Doxorubicin—liver cancer	0.00149	0.00214	CcSEcCtD
Nelarabine—DGUOK—Metabolism—GSTA1—liver cancer	0.00149	0.00574	CbGpPWpGaD
Nelarabine—Blood creatinine increased—Doxorubicin—liver cancer	0.00148	0.00214	CcSEcCtD
Nelarabine—Dehydration—Doxorubicin—liver cancer	0.00147	0.00212	CcSEcCtD
Nelarabine—DGUOK—Metabolism—NAT2—liver cancer	0.00147	0.00568	CbGpPWpGaD
Nelarabine—POLA1—Chromosome Maintenance—H2AFX—liver cancer	0.00146	0.00562	CbGpPWpGaD
Nelarabine—Vomiting—Sorafenib—liver cancer	0.00145	0.00208	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.00145	0.00558	CbGpPWpGaD
Nelarabine—Hypokalaemia—Doxorubicin—liver cancer	0.00144	0.00208	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00143	0.00205	CcSEcCtD
Nelarabine—Headache—Sorafenib—liver cancer	0.00143	0.00205	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.00142	0.00548	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ALDOB—liver cancer	0.00141	0.00545	CbGpPWpGaD
Nelarabine—Muscular weakness—Doxorubicin—liver cancer	0.0014	0.00201	CcSEcCtD
Nelarabine—POLA1—Synthesis of DNA—PCNA—liver cancer	0.00139	0.00535	CbGpPWpGaD
Nelarabine—Neutropenia—Epirubicin—liver cancer	0.00138	0.00199	CcSEcCtD
Nelarabine—Abdominal distension—Doxorubicin—liver cancer	0.00138	0.00198	CcSEcCtD
Nelarabine—POLA1—Chromosome Maintenance—PCNA—liver cancer	0.00136	0.00526	CbGpPWpGaD
Nelarabine—Nausea—Sorafenib—liver cancer	0.00135	0.00195	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CRABP1—liver cancer	0.00135	0.0052	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—CDKN1B—liver cancer	0.00134	0.00516	CbGpPWpGaD
Nelarabine—Hyperglycaemia—Epirubicin—liver cancer	0.00133	0.00192	CcSEcCtD
Nelarabine—Pneumonia—Epirubicin—liver cancer	0.00133	0.00191	CcSEcCtD
Nelarabine—Infestation—Epirubicin—liver cancer	0.00132	0.0019	CcSEcCtD
Nelarabine—Infestation NOS—Epirubicin—liver cancer	0.00132	0.0019	CcSEcCtD
Nelarabine—POLA1—Chromosome Maintenance—TERT—liver cancer	0.00132	0.00508	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—RAF1—liver cancer	0.00131	0.00505	CbGpPWpGaD
Nelarabine—POLA1—DNA Replication—PCNA—liver cancer	0.0013	0.00502	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—CDKN1A—liver cancer	0.0013	0.005	CbGpPWpGaD
Nelarabine—Neuropathy peripheral—Epirubicin—liver cancer	0.00129	0.00186	CcSEcCtD
Nelarabine—Stomatitis—Epirubicin—liver cancer	0.00129	0.00185	CcSEcCtD
Nelarabine—Neutropenia—Doxorubicin—liver cancer	0.00128	0.00184	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CCND1—liver cancer	0.00127	0.00492	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—PCNA—liver cancer	0.00125	0.00483	CbGpPWpGaD
Nelarabine—Hepatobiliary disease—Epirubicin—liver cancer	0.00125	0.0018	CcSEcCtD
Nelarabine—Epistaxis—Epirubicin—liver cancer	0.00124	0.00179	CcSEcCtD
Nelarabine—Sinusitis—Epirubicin—liver cancer	0.00124	0.00178	CcSEcCtD
Nelarabine—Hyperglycaemia—Doxorubicin—liver cancer	0.00123	0.00178	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CDKN1A—liver cancer	0.00123	0.00476	CbGpPWpGaD
Nelarabine—Pneumonia—Doxorubicin—liver cancer	0.00123	0.00177	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—SERPINE1—liver cancer	0.00122	0.00471	CbGpPWpGaD
Nelarabine—Infestation NOS—Doxorubicin—liver cancer	0.00122	0.00176	CcSEcCtD
Nelarabine—Infestation—Doxorubicin—liver cancer	0.00122	0.00176	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1B—liver cancer	0.0012	0.00463	CbGpPWpGaD
Nelarabine—Neuropathy peripheral—Doxorubicin—liver cancer	0.0012	0.00172	CcSEcCtD
Nelarabine—Stomatitis—Doxorubicin—liver cancer	0.00119	0.00171	CcSEcCtD
Nelarabine—Hypoaesthesia—Epirubicin—liver cancer	0.00118	0.0017	CcSEcCtD
Nelarabine—DGUOK—Metabolism—HPGDS—liver cancer	0.00118	0.00454	CbGpPWpGaD
Nelarabine—Urinary tract disorder—Epirubicin—liver cancer	0.00117	0.00168	CcSEcCtD
Nelarabine—Oedema peripheral—Epirubicin—liver cancer	0.00117	0.00168	CcSEcCtD
Nelarabine—Connective tissue disorder—Epirubicin—liver cancer	0.00116	0.00168	CcSEcCtD
Nelarabine—Urethral disorder—Epirubicin—liver cancer	0.00116	0.00167	CcSEcCtD
Nelarabine—Hepatobiliary disease—Doxorubicin—liver cancer	0.00115	0.00166	CcSEcCtD
Nelarabine—Epistaxis—Doxorubicin—liver cancer	0.00115	0.00166	CcSEcCtD
Nelarabine—Sinusitis—Doxorubicin—liver cancer	0.00115	0.00165	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—liver cancer	0.00114	0.00442	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—CDKN2A—liver cancer	0.00114	0.0044	CbGpPWpGaD
Nelarabine—POLA1—S Phase—PCNA—liver cancer	0.00114	0.00439	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—liver cancer	0.00111	0.00427	CbGpPWpGaD
Nelarabine—Eye disorder—Epirubicin—liver cancer	0.00111	0.00159	CcSEcCtD
Nelarabine—Cardiac disorder—Epirubicin—liver cancer	0.0011	0.00158	CcSEcCtD
Nelarabine—Hypoaesthesia—Doxorubicin—liver cancer	0.00109	0.00157	CcSEcCtD
Nelarabine—Urinary tract disorder—Doxorubicin—liver cancer	0.00108	0.00156	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—PPARA—liver cancer	0.00108	0.00417	CbGpPWpGaD
Nelarabine—Oedema peripheral—Doxorubicin—liver cancer	0.00108	0.00155	CcSEcCtD
Nelarabine—Connective tissue disorder—Doxorubicin—liver cancer	0.00108	0.00155	CcSEcCtD
Nelarabine—Angiopathy—Epirubicin—liver cancer	0.00107	0.00155	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—MYC—liver cancer	0.00107	0.00415	CbGpPWpGaD
Nelarabine—Urethral disorder—Doxorubicin—liver cancer	0.00107	0.00155	CcSEcCtD
Nelarabine—Mediastinal disorder—Epirubicin—liver cancer	0.00107	0.00154	CcSEcCtD
Nelarabine—Chills—Epirubicin—liver cancer	0.00106	0.00153	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—PCNA—liver cancer	0.00106	0.00407	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PSMD10—liver cancer	0.00105	0.00405	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PSMA4—liver cancer	0.00105	0.00405	CbGpPWpGaD
Nelarabine—Mental disorder—Epirubicin—liver cancer	0.00104	0.00149	CcSEcCtD
Nelarabine—Malnutrition—Epirubicin—liver cancer	0.00103	0.00148	CcSEcCtD
Nelarabine—Eye disorder—Doxorubicin—liver cancer	0.00102	0.00147	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—MYC—liver cancer	0.00102	0.00395	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GOT2—liver cancer	0.00102	0.00394	CbGpPWpGaD
Nelarabine—Cardiac disorder—Doxorubicin—liver cancer	0.00102	0.00146	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—CDKN1B—liver cancer	0.00101	0.0039	CbGpPWpGaD
Nelarabine—Dysgeusia—Epirubicin—liver cancer	0.00101	0.00145	CcSEcCtD
Nelarabine—ADA—Metabolism—UGDH—liver cancer	0.001	0.00386	CbGpPWpGaD
Nelarabine—Back pain—Epirubicin—liver cancer	0.000997	0.00144	CcSEcCtD
Nelarabine—Angiopathy—Doxorubicin—liver cancer	0.000994	0.00143	CcSEcCtD
Nelarabine—Mediastinal disorder—Doxorubicin—liver cancer	0.000987	0.00142	CcSEcCtD
Nelarabine—Chills—Doxorubicin—liver cancer	0.000983	0.00142	CcSEcCtD
Nelarabine—Vision blurred—Epirubicin—liver cancer	0.000972	0.0014	CcSEcCtD
Nelarabine—Mental disorder—Doxorubicin—liver cancer	0.00096	0.00138	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CYP2E1—liver cancer	0.000959	0.0037	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—RAF1—liver cancer	0.000958	0.0037	CbGpPWpGaD
Nelarabine—Malnutrition—Doxorubicin—liver cancer	0.000954	0.00137	CcSEcCtD
Nelarabine—Anaemia—Epirubicin—liver cancer	0.000953	0.00137	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—KRAS—liver cancer	0.000945	0.00365	CbGpPWpGaD
Nelarabine—ADA—Metabolism—EPT1—liver cancer	0.00094	0.00363	CbGpPWpGaD
Nelarabine—Dysgeusia—Doxorubicin—liver cancer	0.000934	0.00134	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—CDKN1A—liver cancer	0.000932	0.0036	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.000932	0.0036	CbGpPWpGaD
Nelarabine—DCK—Metabolism—UGDH—liver cancer	0.000923	0.00356	CbGpPWpGaD
Nelarabine—Leukopenia—Epirubicin—liver cancer	0.000923	0.00133	CcSEcCtD
Nelarabine—Back pain—Doxorubicin—liver cancer	0.000923	0.00133	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—liver cancer	0.000918	0.00354	CbGpPWpGaD
Nelarabine—Loss of consciousness—Epirubicin—liver cancer	0.000906	0.0013	CcSEcCtD
Nelarabine—Cough—Epirubicin—liver cancer	0.0009	0.0013	CcSEcCtD
Nelarabine—Vision blurred—Doxorubicin—liver cancer	0.000899	0.00129	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CYCS—liver cancer	0.000897	0.00346	CbGpPWpGaD
Nelarabine—Convulsion—Epirubicin—liver cancer	0.000893	0.00129	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—PPARG—liver cancer	0.000893	0.00345	CbGpPWpGaD
Nelarabine—ADA—Metabolism—TAT—liver cancer	0.000892	0.00344	CbGpPWpGaD
Nelarabine—Anaemia—Doxorubicin—liver cancer	0.000882	0.00127	CcSEcCtD
Nelarabine—DGUOK—Metabolism—GGT1—liver cancer	0.00088	0.0034	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GOT1—liver cancer	0.00088	0.0034	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1B—liver cancer	0.000878	0.00339	CbGpPWpGaD
Nelarabine—Myalgia—Epirubicin—liver cancer	0.000878	0.00126	CcSEcCtD
Nelarabine—Chest pain—Epirubicin—liver cancer	0.000878	0.00126	CcSEcCtD
Nelarabine—Arthralgia—Epirubicin—liver cancer	0.000878	0.00126	CcSEcCtD
Nelarabine—DCK—Metabolism—EPT1—liver cancer	0.000868	0.00335	CbGpPWpGaD
Nelarabine—Leukopenia—Doxorubicin—liver cancer	0.000854	0.00123	CcSEcCtD
Nelarabine—Confusional state—Epirubicin—liver cancer	0.000848	0.00122	CcSEcCtD
Nelarabine—Oedema—Epirubicin—liver cancer	0.000841	0.00121	CcSEcCtD
Nelarabine—Loss of consciousness—Doxorubicin—liver cancer	0.000838	0.00121	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—liver cancer	0.000837	0.00323	CbGpPWpGaD
Nelarabine—Infection—Epirubicin—liver cancer	0.000836	0.0012	CcSEcCtD
Nelarabine—Cough—Doxorubicin—liver cancer	0.000832	0.0012	CcSEcCtD
Nelarabine—Convulsion—Doxorubicin—liver cancer	0.000826	0.00119	CcSEcCtD
Nelarabine—Nervous system disorder—Epirubicin—liver cancer	0.000825	0.00119	CcSEcCtD
Nelarabine—Thrombocytopenia—Epirubicin—liver cancer	0.000824	0.00119	CcSEcCtD
Nelarabine—DCK—Metabolism—TAT—liver cancer	0.000823	0.00318	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—PSMA4—liver cancer	0.000818	0.00316	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—PSMD10—liver cancer	0.000818	0.00316	CbGpPWpGaD
Nelarabine—Arthralgia—Doxorubicin—liver cancer	0.000812	0.00117	CcSEcCtD
Nelarabine—Chest pain—Doxorubicin—liver cancer	0.000812	0.00117	CcSEcCtD
Nelarabine—Myalgia—Doxorubicin—liver cancer	0.000812	0.00117	CcSEcCtD
Nelarabine—POLA1—Synthesis of DNA—CDKN1B—liver cancer	0.000811	0.00313	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1A—liver cancer	0.00081	0.00313	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—SERPINE1—liver cancer	0.000804	0.0031	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—HRAS—liver cancer	0.000803	0.0031	CbGpPWpGaD
Nelarabine—Anorexia—Epirubicin—liver cancer	0.000802	0.00115	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.0008	0.00309	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—GSTP1—liver cancer	0.000791	0.00305	CbGpPWpGaD
Nelarabine—Hypotension—Epirubicin—liver cancer	0.000786	0.00113	CcSEcCtD
Nelarabine—Confusional state—Doxorubicin—liver cancer	0.000785	0.00113	CcSEcCtD
Nelarabine—DGUOK—Metabolism—HMOX1—liver cancer	0.00078	0.00301	CbGpPWpGaD
Nelarabine—Oedema—Doxorubicin—liver cancer	0.000778	0.00112	CcSEcCtD
Nelarabine—Infection—Doxorubicin—liver cancer	0.000773	0.00111	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—MYC—liver cancer	0.000773	0.00298	CbGpPWpGaD
Nelarabine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000767	0.0011	CcSEcCtD
Nelarabine—Nervous system disorder—Doxorubicin—liver cancer	0.000763	0.0011	CcSEcCtD
Nelarabine—Thrombocytopenia—Doxorubicin—liver cancer	0.000762	0.0011	CcSEcCtD
Nelarabine—POLA1—DNA Replication—CDKN1B—liver cancer	0.000761	0.00294	CbGpPWpGaD
Nelarabine—Insomnia—Epirubicin—liver cancer	0.000761	0.0011	CcSEcCtD
Nelarabine—Paraesthesia—Epirubicin—liver cancer	0.000755	0.00109	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—liver cancer	0.000754	0.00291	CbGpPWpGaD
Nelarabine—Dyspnoea—Epirubicin—liver cancer	0.00075	0.00108	CcSEcCtD
Nelarabine—POLA1—Synthesis of DNA—CDKN1A—liver cancer	0.000749	0.00289	CbGpPWpGaD
Nelarabine—Somnolence—Epirubicin—liver cancer	0.000748	0.00108	CcSEcCtD
Nelarabine—Anorexia—Doxorubicin—liver cancer	0.000742	0.00107	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—CDKN1B—liver cancer	0.000733	0.00283	CbGpPWpGaD
Nelarabine—Decreased appetite—Epirubicin—liver cancer	0.000731	0.00105	CcSEcCtD
Nelarabine—Hypotension—Doxorubicin—liver cancer	0.000727	0.00105	CcSEcCtD
Nelarabine—DGUOK—Metabolism—GSTM1—liver cancer	0.000727	0.00281	CbGpPWpGaD
Nelarabine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000726	0.00105	CcSEcCtD
Nelarabine—Fatigue—Epirubicin—liver cancer	0.000725	0.00104	CcSEcCtD
Nelarabine—Pain—Epirubicin—liver cancer	0.000719	0.00104	CcSEcCtD
Nelarabine—Constipation—Epirubicin—liver cancer	0.000719	0.00104	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000709	0.00102	CcSEcCtD
Nelarabine—Insomnia—Doxorubicin—liver cancer	0.000704	0.00101	CcSEcCtD
Nelarabine—POLA1—DNA Replication—CDKN1A—liver cancer	0.000702	0.00271	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000702	0.00271	CbGpPWpGaD
Nelarabine—Paraesthesia—Doxorubicin—liver cancer	0.000699	0.00101	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—liver cancer	0.000697	0.00269	CbGpPWpGaD
Nelarabine—Dyspnoea—Doxorubicin—liver cancer	0.000694	0.000999	CcSEcCtD
Nelarabine—Feeling abnormal—Epirubicin—liver cancer	0.000693	0.000998	CcSEcCtD
Nelarabine—Somnolence—Doxorubicin—liver cancer	0.000692	0.000996	CcSEcCtD
Nelarabine—DGUOK—Metabolism—CYP1A1—liver cancer	0.000689	0.00266	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000688	0.00266	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Epirubicin—liver cancer	0.000688	0.00099	CcSEcCtD
Nelarabine—Decreased appetite—Doxorubicin—liver cancer	0.000677	0.000974	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—CDKN1A—liver cancer	0.000676	0.00261	CbGpPWpGaD
Nelarabine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000672	0.000968	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—liver cancer	0.000672	0.00259	CbGpPWpGaD
Nelarabine—Fatigue—Doxorubicin—liver cancer	0.000671	0.000966	CcSEcCtD
Nelarabine—Constipation—Doxorubicin—liver cancer	0.000666	0.000958	CcSEcCtD
Nelarabine—Pain—Doxorubicin—liver cancer	0.000666	0.000958	CcSEcCtD
Nelarabine—POLA1—S Phase—CDKN1B—liver cancer	0.000665	0.00257	CbGpPWpGaD
Nelarabine—Abdominal pain—Epirubicin—liver cancer	0.000665	0.000958	CcSEcCtD
Nelarabine—Body temperature increased—Epirubicin—liver cancer	0.000665	0.000958	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000651	0.00251	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—MTHFR—liver cancer	0.000642	0.00248	CbGpPWpGaD
Nelarabine—Feeling abnormal—Doxorubicin—liver cancer	0.000641	0.000924	CcSEcCtD
Nelarabine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000637	0.000916	CcSEcCtD
Nelarabine—POLA1—S Phase—CCND1—liver cancer	0.000635	0.00245	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—JUN—liver cancer	0.000633	0.00244	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PPARA—liver cancer	0.00063	0.00243	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN1B—liver cancer	0.000618	0.00238	CbGpPWpGaD
Nelarabine—Abdominal pain—Doxorubicin—liver cancer	0.000615	0.000886	CcSEcCtD
Nelarabine—Body temperature increased—Doxorubicin—liver cancer	0.000615	0.000886	CcSEcCtD
Nelarabine—POLA1—S Phase—CDKN1A—liver cancer	0.000614	0.00237	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—PSMA4—liver cancer	0.000612	0.00236	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—PSMD10—liver cancer	0.000612	0.00236	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CPT1B—liver cancer	0.000606	0.00234	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GLUL—liver cancer	0.000606	0.00234	CbGpPWpGaD
Nelarabine—Asthenia—Epirubicin—liver cancer	0.000604	0.000869	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—MAPK8—liver cancer	0.000599	0.00231	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCND1—liver cancer	0.000589	0.00227	CbGpPWpGaD
Nelarabine—ADA—Metabolism—NR1H4—liver cancer	0.000584	0.00226	CbGpPWpGaD
Nelarabine—Diarrhoea—Epirubicin—liver cancer	0.000576	0.000829	CcSEcCtD
Nelarabine—ADA—Metabolism—GSTA3—liver cancer	0.000575	0.00222	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN1A—liver cancer	0.00057	0.0022	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—MYC—liver cancer	0.000561	0.00216	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GLUL—liver cancer	0.000559	0.00216	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CPT1B—liver cancer	0.000559	0.00216	CbGpPWpGaD
Nelarabine—Asthenia—Doxorubicin—liver cancer	0.000559	0.000804	CcSEcCtD
Nelarabine—Dizziness—Epirubicin—liver cancer	0.000556	0.000801	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—H2AFX—liver cancer	0.000553	0.00213	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—liver cancer	0.000552	0.00213	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—PSMD10—liver cancer	0.000547	0.00211	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—PSMA4—liver cancer	0.000547	0.00211	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PIK3CG—liver cancer	0.00054	0.00208	CbGpPWpGaD
Nelarabine—DCK—Metabolism—NR1H4—liver cancer	0.000539	0.00208	CbGpPWpGaD
Nelarabine—Vomiting—Epirubicin—liver cancer	0.000535	0.00077	CcSEcCtD
Nelarabine—Diarrhoea—Doxorubicin—liver cancer	0.000533	0.000767	CcSEcCtD
Nelarabine—DCK—Metabolism—GSTA3—liver cancer	0.00053	0.00205	CbGpPWpGaD
Nelarabine—Headache—Epirubicin—liver cancer	0.000527	0.000759	CcSEcCtD
Nelarabine—ADA—Metabolism—GSTA4—liver cancer	0.000525	0.00203	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PPARG—liver cancer	0.000521	0.00201	CbGpPWpGaD
Nelarabine—Dizziness—Doxorubicin—liver cancer	0.000515	0.000741	CcSEcCtD
Nelarabine—ADA—Metabolism—GSTA2—liver cancer	0.000512	0.00198	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000511	0.00197	CbGpPWpGaD
Nelarabine—POLA1—S Phase—MYC—liver cancer	0.000509	0.00197	CbGpPWpGaD
Nelarabine—Nausea—Epirubicin—liver cancer	0.0005	0.000719	CcSEcCtD
Nelarabine—Vomiting—Doxorubicin—liver cancer	0.000495	0.000713	CcSEcCtD
Nelarabine—ADA—Metabolism—GSTA1—liver cancer	0.000494	0.00191	CbGpPWpGaD
Nelarabine—ADA—Metabolism—NAT2—liver cancer	0.000488	0.00189	CbGpPWpGaD
Nelarabine—Headache—Doxorubicin—liver cancer	0.000488	0.000702	CcSEcCtD
Nelarabine—DCK—Metabolism—GSTA4—liver cancer	0.000485	0.00187	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PIK3CD—liver cancer	0.000474	0.00183	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—MYC—liver cancer	0.000473	0.00182	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTA2—liver cancer	0.000473	0.00182	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ALB—liver cancer	0.000468	0.00181	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ALDOB—liver cancer	0.000468	0.00181	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000468	0.00181	CbGpPWpGaD
Nelarabine—Nausea—Doxorubicin—liver cancer	0.000462	0.000666	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000459	0.00177	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTA1—liver cancer	0.000456	0.00176	CbGpPWpGaD
Nelarabine—DCK—Metabolism—NAT2—liver cancer	0.000451	0.00174	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CRABP1—liver cancer	0.000447	0.00172	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000446	0.00172	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000445	0.00172	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000442	0.00171	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ALDOB—liver cancer	0.000432	0.00167	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000432	0.00167	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.000421	0.00163	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TP53—liver cancer	0.000418	0.00161	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PIK3CB—liver cancer	0.000414	0.0016	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—H2AFX—liver cancer	0.000413	0.0016	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CRABP1—liver cancer	0.000412	0.00159	CbGpPWpGaD
Nelarabine—ADA—Metabolism—HPGDS—liver cancer	0.000391	0.00151	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.000389	0.0015	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—PCNA—liver cancer	0.000387	0.00149	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—IL6—liver cancer	0.000383	0.00148	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—H2AFX—liver cancer	0.00037	0.00143	CbGpPWpGaD
Nelarabine—DCK—Metabolism—HPGDS—liver cancer	0.00036	0.00139	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	0.000358	0.00138	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	0.000357	0.00138	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PSMA4—liver cancer	0.000348	0.00134	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PSMD10—liver cancer	0.000348	0.00134	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—PCNA—liver cancer	0.000346	0.00134	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GOT2—liver cancer	0.000339	0.00131	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TERT—liver cancer	0.000334	0.00129	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	0.000334	0.00129	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	0.000331	0.00128	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PSMD10—liver cancer	0.000321	0.00124	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PSMA4—liver cancer	0.000321	0.00124	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CYP2E1—liver cancer	0.000318	0.00123	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GOT2—liver cancer	0.000312	0.00121	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	0.000304	0.00117	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CYCS—liver cancer	0.000298	0.00115	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	0.000294	0.00114	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CYP2E1—liver cancer	0.000294	0.00113	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GOT1—liver cancer	0.000292	0.00113	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GGT1—liver cancer	0.000292	0.00113	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CYCS—liver cancer	0.000275	0.00106	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GGT1—liver cancer	0.00027	0.00104	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GOT1—liver cancer	0.00027	0.00104	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GSTP1—liver cancer	0.000263	0.00101	CbGpPWpGaD
Nelarabine—ADA—Metabolism—HMOX1—liver cancer	0.000259	0.000999	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—liver cancer	0.000256	0.000987	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PIK3CA—liver cancer	0.000252	0.000973	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	0.000248	0.000958	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTP1—liver cancer	0.000242	0.000935	CbGpPWpGaD
Nelarabine—ADA—Metabolism—GSTM1—liver cancer	0.000241	0.000931	CbGpPWpGaD
Nelarabine—DCK—Metabolism—HMOX1—liver cancer	0.000239	0.000922	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CYP1A1—liver cancer	0.000229	0.000883	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN2A—liver cancer	0.000229	0.000883	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN1B—liver cancer	0.000227	0.000874	CbGpPWpGaD
Nelarabine—DCK—Metabolism—GSTM1—liver cancer	0.000223	0.000859	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCND1—liver cancer	0.000216	0.000834	CbGpPWpGaD
Nelarabine—ADA—Metabolism—MTHFR—liver cancer	0.000213	0.000823	CbGpPWpGaD
Nelarabine—DCK—Metabolism—CYP1A1—liver cancer	0.000211	0.000815	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PPARA—liver cancer	0.000209	0.000807	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN1A—liver cancer	0.000209	0.000807	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—AKT1—liver cancer	0.000206	0.000795	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN1B—liver cancer	0.000203	0.000782	CbGpPWpGaD
Nelarabine—DCK—Metabolism—MTHFR—liver cancer	0.000197	0.00076	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CCND1—liver cancer	0.000193	0.000746	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PPARA—liver cancer	0.000193	0.000745	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN1A—liver cancer	0.000187	0.000722	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CG—liver cancer	0.000179	0.000692	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—MYC—liver cancer	0.000173	0.000669	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PPARG—liver cancer	0.000173	0.000667	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CG—liver cancer	0.000165	0.000638	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PPARG—liver cancer	0.00016	0.000616	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CD—liver cancer	0.000157	0.000608	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ALB—liver cancer	0.000155	0.0006	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MYC—liver cancer	0.000155	0.000598	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CD—liver cancer	0.000145	0.000561	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ALB—liver cancer	0.000143	0.000554	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CB—liver cancer	0.000137	0.00053	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TP53—liver cancer	0.000127	0.000491	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CB—liver cancer	0.000127	0.000489	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CA—liver cancer	8.37e-05	0.000323	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CA—liver cancer	7.72e-05	0.000298	CbGpPWpGaD
Nelarabine—ADA—Metabolism—AKT1—liver cancer	6.84e-05	0.000264	CbGpPWpGaD
Nelarabine—DCK—Metabolism—AKT1—liver cancer	6.31e-05	0.000244	CbGpPWpGaD
